Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-05-04

Clinical Trial Update: Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Fingolimod for acute demyelinating optic neuritis; the study was terminated and results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Fingolimod (Gilenya) (fingolimod)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acute Demylelinating Optic Neuritis | Phase 2 | Status: TERMINATED | Results posted: 2015-05-04